The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Weak to moderate nuclear immunoreactivity was observed in most malignancies. A few malignant gliomas, prostate and pancreatic cancer as well as head and neck cancer were strongly stained. Renal cancers were weakly stained or negative.
Moderate to strong nuclear immunoreactivity was observed in most malignant tissues. Colorectal, breast and pancreatic cancers were strongly stained in several cases.
Malignant cells displayed moderate to strong nuclear immunoreactivity. Hepatocellular carcinomas and several malignant gliomas, renal cell carcinomas were weakly stained or negative.
Validation
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
